Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596086 · ClinicalTrials.gov registry record · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
A Phase 1 study of Glioblastoma Multiforme and Astrocytoma, Grade III, sponsored by David Baskin MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT03596086: Recruiting Phase 1 study of Glioblastoma Multiforme and Astrocytoma, Grade III, sponsored by David Baskin MD.
NCT03596086 is a Phase 1 study of Glioblastoma Multiforme and Astrocytoma, Grade III that is actively recruiting participants, run by David Baskin MD. The registered enrollment target is 62 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03596086, a Phase 1 study of Glioblastoma Multiforme and Astrocytoma, Grade III, is actively recruiting participants, sponsored by David Baskin MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
Primary Outcome
The overall survival in months of recurrent GBM patients drug administration up to five years
Conditions Studied
Interventions
- DRUG ADV/HSV-tk (gene therapy)
Study Locations (1)
Texas
- Houston Methodist Neurological Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
What NCT03596086 shows while recruiting
NCT03596086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (35% lower).
The record links to 2 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which ADV/HSV-tk (gene therapy) is the first listed.
NCT03596086 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03596086 about?
NCT03596086 is a clinical study titled "HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM". Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
What is the current status of trial NCT03596086?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2017-12-11. Estimated completion is 2025-12-30.
What conditions does trial NCT03596086 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Astrocytoma, Grade III.
What interventions are being tested in trial NCT03596086?
The interventions under investigation include: ADV/HSV-tk (gene therapy) (DRUG).
Who is sponsoring clinical trial NCT03596086?
This trial is sponsored by David Baskin MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03596086 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03596086's enrollment target sits among peer trials
62 29th of 88 higher than 60 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
- NCT03904498 · 62 participants · Phase 2
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI